SUPPLEMENTARY TABLE

Characteristics of persons with SARS-CoV-2 infection by receipt of follow-up SARS-CoV-2 antigen test to assess early termination of isolation — Yukon-Kuskokwim Delta region, Alaska, January–February 2022

	n/N (%)		
Characteristic	**Received follow-up SARS-CoV-2 antigen test* (N = 729)†**	**Did not receive follow-up SARS-CoV-2 antigen test* (N = 2,537)†**	**p-value for difference§**
Median age, yrs (IQR)	30 (17–45)	22 (11–39)	<0.001
Female sex	380/729 (52.1)	1,343/2,508 (53.5)	0.235
Alaska Native / American Indian¶	666/729 (91.4)	2,364/2,537 (93.2)	0.094
Vaccinated**	541/729 (74.2)	1,519/2,537 (59.9)	<0.001
Symptoms reported††	564/729 (77.4)	1,957/2,407 (81.3)	0.119
Calendar week of initial test§§			
January 1–7	88/729 (12.1)	334/2,537 (13.2)	<0.001
January 8–14	90/729 (12.3)	548/2,537 (21.6)	
January 15–21	139/729 (19.1)	526/2,537 (20.7)	
January 22–28	214/729 (29.4)	546/2,537 (21.5)	
January 29–February 4	198/729 (27.2)	583/2,537 (23.0)	

* An Abbott BinaxNOW COVID-19 Ag (BinaxNOW) rapid antigen test was offered to all persons reporting no symptoms or resolving symptoms 5–9 days after symptom onset (or after the first positive test if asymptomatic), and if no fever was reported for at least 24 hours without fever-reducing medications.

† During January 1–February 9, 2022, 3,502 persons with SARS-CoV-2 infection were reported to Yukon-Kuskokwim Health Corporation, including 3,266 (93.3%) for whom symptom onset (if symptomatic) or the initial positive test result (if asymptomatic) had occurred 5–9 days earlier. Denominators vary because missing values were excluded.

§ Calculated using the Chi-square test.

¶ Compared with other race.

** Received a primary COVID-19 vaccination series, defined as 2 doses of an mRNA COVID-19 vaccine (Pfizer-BioNTech or Moderna) or 1 dose of the Johnson & Johnson (Janssen) vaccine ≥14 days earlier.

†† Symptoms reported at initial encounter (both groups); persons receiving a follow-up SARS-CoV-2 BinaxNOW antigen test could also report symptoms at that time.

§§ Positive SARS-CoV-2 nucleic acid amplification test or antigen test.